Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04013854 · ClinicalTrials.gov registry record · Phase 2
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
A Phase 2 study of Melanoma and Melanoma Stage III, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
- 3
- Study locations
NCT04013854 is a Phase 2 study of Melanoma and Melanoma Stage III that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 67 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04013854, a Phase 2 study of Melanoma and Melanoma Stage III, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
- 3
- Study locations
Study Summary
Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.
Conditions Studied
Interventions
- DRUG Ipilimumab
- DRUG nivolumab
Study Locations (3)
Pennsylvania
- Lancaster General Hospital - Lancaster
- Abramson Cancer Center, University of Pennsylvania - Philadelphia
North Carolina
- Duke Cancer Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2026-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04013854
The ClinicalTrials.gov registry entry for NCT04013854 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Ipilimumab is the first listed.
NCT04013854 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Pennsylvania, North Carolina.
Frequently Asked Questions
What is clinical trial NCT04013854 about?
NCT04013854 is a clinical study titled "Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab". Subjects with resectable melanoma will receive neoadjuvant nivolumab followed by surgical resection. Post-operatively, subjects will receive open-label treatment with up to 1 year of adjuvant nivolumab or ipilimumab plus nivolumab as determined by pathologic response at the time of resection.
What is the current status of trial NCT04013854?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2020-01-01. Estimated completion is 2026-08.
What conditions does trial NCT04013854 study?
This clinical trial studies the following conditions: Melanoma, Melanoma Stage III.
What interventions are being tested in trial NCT04013854?
The interventions under investigation include: Ipilimumab (DRUG), nivolumab (DRUG).
Who is sponsoring clinical trial NCT04013854?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04013854 being conducted?
This trial has 3 study locations across North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.